New Drugs to Stop Growth of Brain and Breast Cancer
Researchers at the University of Hawaii Cancer Centre in the US have discovered two new compounds which inhibit the growth of breast and brain tumors.The researchers examined compounds that inhibited Stat3 signaling pathway, implicated in various brain and breast cancers. The two chemical compounds, a hydroxamic acid-based inhibitor (SH5-07), and a benzoic acid-based...
Login or Register to read the full article
Researchers at the University of Hawaii Cancer Centre in the US have discovered two new compounds which inhibit the growth of breast and brain tumors.
The researchers examined compounds that inhibited Stat3 signaling pathway, implicated in various brain and breast cancers. The two chemical compounds, a hydroxamic acid-based inhibitor (SH5-07), and a benzoic acid-based inhibitor (SH4-54) inhibited Stat3 protein.
"It is particularly encouraging for brain tumor patients, who do not currently have effective treatment options besides surgery," said James Turkson from University of Hawaii Cancer Centre in the US.
"The targeted treatments are less toxic and therefore will give cancer patients a better quality of life when both compounds are developed as drugs," Turkson said. "Our results offer preclinical proof of concept for SH5-07 and SH4-54 as candidates for further development as cancer therapeutics."
The study was published in the Journal Cancer Research.
The researchers examined compounds that inhibited Stat3 signaling pathway, implicated in various brain and breast cancers. The two chemical compounds, a hydroxamic acid-based inhibitor (SH5-07), and a benzoic acid-based inhibitor (SH4-54) inhibited Stat3 protein.
"It is particularly encouraging for brain tumor patients, who do not currently have effective treatment options besides surgery," said James Turkson from University of Hawaii Cancer Centre in the US.
"The targeted treatments are less toxic and therefore will give cancer patients a better quality of life when both compounds are developed as drugs," Turkson said. "Our results offer preclinical proof of concept for SH5-07 and SH4-54 as candidates for further development as cancer therapeutics."
The study was published in the Journal Cancer Research.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd